Skip to Content

Methscopolamine Dosage

Applies to the following strength(s): 2.5 mg ; 5 mg

The information at is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for Peptic Ulcer

Adjunctive therapy:
Average dose: 2.5 mg orally one-half hour before meals and 2.5 to 5 mg at bedtime

If patients are experiencing symptoms such as severe abdominal pain or cramping which demand prompt relief, methscopolamine may be started on a daily dosage of 20 mg, administered in doses of 5 mg orally one-half hour before meals and at bedtime.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

If unpleasant side effects develop promptly, the daily dosage should be reduced. If neither symptomatic relief nor side effects appear, the daily dosage may be increased. Some patients have tolerated 30 mg/day without unpleasant side effects.

The goal of therapy is to find a dosage which provides maximal clinical effectiveness with a minimum of unpleasant side effects. Many patients report no side effects on a dosage which gives complete symptom relief. However, some patients have reported severe side effects without appreciable symptom relief. Such patients must be considered unsuited for this therapy. Usually they have been or will prove to be similarly intolerant to other anticholinergic drugs. If methscopolamine is to be used in a patient who gives a history of such intolerance, it should be started at a low dosage.


Methscopolamine is contraindicated in patients with glaucoma, obstructive uropathy, obstructive disease of the gastrointestinal tract, paralytic ileus, intestinal atony of the elderly or debilitated patient, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, and myasthenia gravis.

Because gastrointestinal antispasmodics are highly anticholinergic drugs, methscopolamine meets Beers criteria as a medication that is potentially inappropriate for use in older adults.

With overdose, a curare-like action may occur, characterized by muscular weakness and possible paralysis.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).


Data not available

Other Comments

Patients whose dosage has been reduced to eliminate or modify side effects often continue to show adequate response both subjectively in relief of symptoms and objectively as measured by antisecretory effects.

Patients should be cautioned regarding activities requiring mental alertness (such as operating a motor vehicle or other machinery or performing hazardous work) while taking methscopolamine.